BioMarin
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
BMRN Key Statistics
Stock Snapshot
With a market cap of 11.49B, BioMarin(BMRN) trades at $59.50. The stock has a price-to-earnings ratio of 34.21.
On 2026-03-02, BioMarin(BMRN) stock moved within a range of $59.31 to $61.73. With shares now at $59.50, the stock is trading +0.3% above its intraday low and -3.6% below the session's peak.
Trading volume for BioMarin(BMRN) stock has reached 1.95M, versus its average volume of 2.59M.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.76.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.76.
BMRN News
BioMarin (BMRN) Pharmaceutical announced that the U.S. Food and Drug Administration, FDA, has approved the company’s supplemental Biologics License Application,...
Advertisement Event driven snapshot of BioMarin Pharmaceutical BioMarin Pharmaceutical (BMRN) is back on investor radars after recent share price moves, with...
Canaccord analyst Whitney Ijem raised the firm’s price target on BioMarin (BMRN) to $104 from $98 and keeps a Buy rating on the shares. The firm said its 4Q25 e...
Analyst ratings
81%
of 26 ratingsMore BMRN News
BioMarin Pharmaceutical has entered into a definitive agreement to acquire Amicus Therapeutics. The deal marks a major change for Amicus Therapeutics and its c...
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on BioMarin (BMRN) to $55 from $60 and keeps a Neutral rating on the shares. The firm sa...
Biomarin Pharmaceutical Inc. ((BMRN)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fu...
BofA lowered the firm’s price target on BioMarin (BMRN) to $97 from $102 and keeps a Buy rating on the shares. The firm’s lowered target reflects competitive he...
William Blair analyst Sami Corwin has maintained their neutral stance on BMRN stock, giving a Hold rating on February 17. Sami Corwin has given his Hold rating...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.